Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Francesco Crescenzo
Observed names:
Crescenzo, F.,
Crescenzo, Francesco,
F. Crescenzo
Institutions:
University of Verona,
Azienda ULSS 9 Scaligera
Observed institutions:
University of Verona,
University of Catania,
Azienda Ospedaliera Universitaria Integrata Verona,
Policlinico Universitario di Catania,
Azienda ULSS 9 Scaligera
ORCID:
0000-0003-1396-7774
Observed ORCID:
0000-0003-1396-7774
OpenAlex ID:
A5001858028
Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis
2020
·
M.A. Clarke
, D. Pareto
, et al.
·
American Journal of Neuroradiology
·
144
PDF
The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis
2020
·
Marco Castellaro
, Agnese Tamanti
, et al.
·
Diagnostics
·
102
PDF
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
2021
·
Maria Pia Sormani
, Irene Schiavetti
, et al.
·
Neurology Neuroimmunology & Neuroinflammation
·
79
PDF
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
2021
·
Maria Pia Sormani
, Irene Schiavetti
, et al.
·
Multiple Sclerosis Journal
·
52
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis
2021
·
Damiano Marastoni
, Roberta Magliozzi
, et al.
·
Neurology Neuroimmunology & Neuroinflammation
·
40
PDF
The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse?
2024
·
Valentina Mazziotti
, Francesco Crescenzo
, et al.
·
Journal of Neuroinflammation
·
37
PDF
Coping Strategies and Their Impact on Quality of Life and Physical Disability of People with Multiple Sclerosis
2021
·
Silvia Cerea
, Marta Ghisi
, et al.
·
Journal of Clinical Medicine
·
29
PDF
A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
2021
·
Anna Isabella Pisani
, Antonio Scalfari
, et al.
·
European Journal of Neurology
·
29
PDF
Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy
2020
·
Francesco Crescenzo
, Damiano Marastoni
, et al.
·
Multiple Sclerosis and Related Disorders
·
28
PDF
Cortical lesions at diagnosis predict long‐term cognitive impairment in multiple sclerosis: A 20‐year study
2023
·
Stefano Ziccardi
, Anna Isabella Pisani
, et al.
·
European Journal of Neurology
·
27
PDF
Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study
2019
·
Damiano Marastoni
, Alessandro Buriani
, et al.
·
Frontiers in Immunology
·
25
PDF
Early regional cerebral grey matter damage predicts long-term cognitive impairment phenotypes in multiple sclerosis: a 20-year study
2024
·
Stefano Ziccardi
, Francesco Crescenzo
, et al.
·
Brain Communications
·
21
“What Is Hidden behind the Mask?” Facial Emotion Recognition at the Time of COVID-19 Pandemic in Cognitively Normal Multiple Sclerosis Patients
2021
·
Stefano Ziccardi
, Francesco Crescenzo
, et al.
·
Diagnostics
·
16
PDF
Early multiple sclerosis: diagnostic challenges in clinically and radiologically isolated syndrome patients
2021
·
Massimiliano Calabrese
, Damiano Marastoni
, et al.
·
Current Opinion in Neurology
·
16
Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients
2020
·
Roberta Magliozzi
, Valentina Mazziotti
, et al.
·
Frontiers in Cellular Neuroscience
·
15
PDF
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis
2025
·
Damiano Marastoni
, Elisa Colato
, et al.
·
Neurology Neuroimmunology & Neuroinflammation
·
14
Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS
2021
·
Albulena Bajrami
, Roberta Magliozzi
, et al.
·
Multiple Sclerosis Journal
·
14
CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis
2024
·
Damiano Marastoni
, Matteo Foschi
, et al.
·
Frontiers in Immunology
·
12
PDF
CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis
2022
·
Damiano Marastoni
, Anna I. Pisani
, et al.
·
Therapeutic Advances in Neurological Disorders
·
12
PDF
Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis
2018
·
F. Crescenzo
, D. Marastoni
, et al.
·
Multiple Sclerosis and Related Disorders
·
10
Eculizumab as Additional Rescue Therapy in Myasthenic Crisis
2024
·
Francesco Crescenzo
, Mattia Zanoni
, et al.
·
Muscles
·
9
PDF
Two years’ effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis
2022
·
Damiano Marastoni
, Francesco Crescenzo
, et al.
·
Multiple Sclerosis Journal
·
9
Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course
2025
·
Stefano Ziccardi
, Maddalena Guandalini
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
5
Chronic Central Nervous System Graft-Versus-Host Disease to Unravel Progressive Visual Loss and Ischemic Stroke Recurrence Post-Allogeneic Hematopoietic Stem Cell Transplant: A Case Report
2025
·
Francesco Crescenzo
, Alessandra Danese
, et al.
·
International Journal of Molecular Sciences
·
5
Cognition beyond relapses: cognitive progression independent of relapse activity reflects early smoldering neurodegeneration in multiple sclerosis
2026
·
Stefano Ziccardi
, Tom A Fuchs
, et al.
·
Multiple Sclerosis and Related Disorders
·
4
PDF
Show more works
View as search
Works count:
39
Citation count:
768
H-index:
15
I10-index:
20
Year
Topic
Type